Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 11/20 | 0.67 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.67 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.56 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902721 | 0.79 | SHMT2 (0.77) | MKNK2MKNK1SHMT2MAPTSMN1; SMN2 | |
| SCHEMBL4909670 | 0.76 | MKNK2 (0.71) | MKNK2MKNK1SHMT2MAPTSMN1; SMN2 | |
| SCHEMBL15426163 | 0.76 | FGFR1 (0.67) | MKNK2MKNK1SHMT2CSNK2A2CSNK2B | |
| SCHEMBL14214405 | 0.76 | MAPT (0.57) | MKNK2MKNK1MAPTSMN1; SMN2RXFP1 | |
| SCHEMBL3345046 | 0.75 | TP53 (0.69) | KDM4EMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL14184143 | 0.73 | KDR (0.54) | MAPTRXFP1TP53DYRK1A | |
| SCHEMBL6112985 | 0.73 | MKNK2 (0.89) | MKNK2MKNK1SHMT2 | |
| SCHEMBL16919150 | 0.72 | MKNK2 (1.00) | MKNK2MKNK1 | |
| SCHEMBL13522552 | 0.72 | MKNK2 (0.60) | MKNK2MKNK1SHMT2MAPT | |
| SCHEMBL2404390 | 0.72 | MKNK2 (0.82) | MKNK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDRENS MEDICAL CENTER (US) | 2026-04-30 | — | — | US | disclosed |
| US-12171755-B2 | PAPD5 inhibitors and methods of use thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-20210177827-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20210177827-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171755-B2 | PAPD5 inhibitors and methods of use thereof | PARP15, PAPSS1, PGA5 | MKNK2 1913/4885MKNK1 2300/4885SHMT2 2152/4885 |
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, TERT, BRCA1 | MKNK2 3487/4885MKNK1 3313/4885SHMT2 863/4885 |
| US-20210177827-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | PARP15, PAPSS1, PGA5 | MKNK2 1913/4885MKNK1 2300/4885SHMT2 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.